Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 20;14(1):6692.
doi: 10.1038/s41598-024-56873-x.

Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding

H Rehman  1 , S T Rehman  1 , S Zulfiqar  1 , S Awan  1 , Shahab Abid  2
Affiliations
Review

Real-world comparison of terlipressin vs. octreotide as an adjuvant treatment in the management of variceal bleeding

H Rehman et al. Sci Rep. .

Abstract

Variceal bleeding is a major complication and the leading cause of death in patients with cirrhosis and portal hypertension. This study aims to compare the efficacy and safety of terlipressin vs octreotide as an adjuvant to endoscopic management of patients with esophageal variceal bleeding in a real-time scenario. We reviewed the medical records of patients with esophageal variceal bleeding from January 2005 to December 2020 at our tertiary care Aga Khan University Hospital. Mortality was assessed after 6 weeks. A total of 842 patients with variceal bleed were evaluated. 624 patients (74.1%) and 218 patients (25.9%) received Terlipressin and Octreotide respectively. On multiple regression analysis, cardiac events during hospital stay (OR: 11.22), presence of Porto-systemic encephalopathy (OR: 3.79), and elevated bilirubin levels at the time of presentation were found to be independent risk factors for increased six weeks mortality. Moreover, cardiac events during hospital stay (OR: 3.26), Porto-systemic encephalopathy at presentation (OR: 3.06), and octreotide administration (OR: 1.80) were identified as independent risk factors for increased length of hospital stay. Terlipressin and Octreotide have similar outcomes in terms of control of bleeding, hospital stay, mortality, and side effects when used as adjuvant therapy for the management of variceal bleeding.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow chart representing the methodology of stratifying data in this cohort.
Figure 2
Figure 2
Log rank curve depicting the difference in the length of hospital stay between terlipressin and octreotide groups.
See this image and copyright information in PMC

References

    1. García-Pagán J, Reverter E, Abraldes J, Bosch J. Acute variceal bleeding. Semin. Respir. Crit. Care Med. 2012;33(01):46–54. doi: 10.1055/s-0032-1301734. - DOI - PubMed
    1. Wang C, Han J, Xiao L, Jin C, Li D, Yang Z. Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: A systematic review and meta-analysis. Hepatol. Int. 2015;9(1):120–129. doi: 10.1007/s12072-014-9594-9. - DOI - PubMed
    1. Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J, et al. Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97(48):e13437. doi: 10.1097/MD.0000000000013437. - DOI - PMC - PubMed
    1. Hernández-Gea V, Berbel C, Baiges A, García-Pagán JC. Acute variceal bleeding: risk stratification and management (including TIPS) Hepatol Int. 2018;12(S1):81–90. doi: 10.1007/s12072-017-9804-3. - DOI - PubMed
    1. Bhutta AQ, Garcia-Tsao G. The role of medical therapy for variceal bleeding. Gastrointest. Endosc. Clin. N. Am. 2015;25(3):479–490. doi: 10.1016/j.giec.2015.03.001. - DOI - PubMed

MeSH terms